Omid Hamid

22PUBLICATIONS
179CO-AUTHORS
Medical devicesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Feb 16, 2026
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Jul 25, 2025
First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.

Omid Hamid, Dana B Cardin, F Stephen Hodi

|Jul 09, 2025
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

John D Powderly, Martin E Gutierrez, Ani S Balmanoukian

|Jul 09, 2025
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.

Martin E Gutierrez, Shou-Ching Tang, John D Powderly

|Jun 02, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Theresa Medina, Jason A Chesney, Harriet M Kluger

|Jan 09, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.

Sylvia M Lee, Omid Hamid, Robert Jotte

Pageof 4

Frequent Collaborators

3 joint publications

Inderjit Mehmi

3 joint publications

Georgina V Long

3 joint publications

Jeffrey Chou

3 joint publications

James M G Larkin